Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00987948 · ClinicalTrials.gov registry record · Phase 2
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
A Phase 2 study, sponsored by University of Hawaii.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00987948: Completed Phase 2 study, sponsored by University of Hawaii.
NCT00987948 is a Phase 2 study that has completed, run by University of Hawaii. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00987948, a Phase 2 study, has completed, sponsored by University of Hawaii.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy (MRS, a form of MRI study).
Primary Outcome
Week 24 minus baseline
Interventions
- DRUG maraviroc (Selzentry)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
What the finished NCT00987948 record still lists
NCT00987948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which maraviroc (Selzentry) is the first listed.
NCT00987948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00987948 about?
NCT00987948 is a clinical study titled "Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels". High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a rece...
What is the current status of trial NCT00987948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-01. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00987948?
The interventions under investigation include: maraviroc (Selzentry) (DRUG).
Who is sponsoring clinical trial NCT00987948?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00987948's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia